BioBusiness

Industry may be its own obstacle to success in achieving the desired high-performance state.

Are biosimilars the next big thing or just the next big bubble?

Insights from real-time ranking of global biomanufacturing capabilities.

Which route will we take to arrive at a national stem-cell policy?

Strong pipelines, approvals, and deals drive up market cap.

BIO's president and CEO provides insight leading up to the 2011 convention.

Patent databases are often overlooked as a source of basic science, research, and development

Knowing where key biomanufacturing facilities are located around the world is essential for decision-making.

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Two films portray, in surprising detail, the hard work and determination of the biopharmaceutical industry.

Research and development headed for divorce.

Industry starts the year with a positive spin.

Those at the top must walk the walk of uncompromising commitment to compliance

How did biopharmaceutical professionals fare during a year of hiring freezes, high anxiety, and increased workload? Our survey finds out.

Why this workforce trend is well-suited for pharmaceutical companies.

Business models that were used to create current value are no longer going to be effective going forward.

To achieve manufacturing excellence, biopharma companies must adopt four key operating principles.

Managing partnerships for the greater good.

Biotech approvals were up last year. Is it a sign of a new trend?

Biotech's mid-sized elites position themselves for growth.

An in-depth analysis of the patent provisions of the new legislation.

In light of the new ruling, patent licensees may want to re-evaluate the strength of their licensed patents.

After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.

Thomson Reuters' Mark Gordon looks at how real partnership opportunities are developing in a virtual pharma world.

Combine cost analyses with QbD to improve operations and lower costs.